Why pharma marketing technology has to be co-authored with the people who use it.
Pharma marketing technology has never been more capable. The platforms are more sophisticated, the data more precise, the AI more powerful than at any point in the industry's history. And yet, the experience on the ground tells a different story. Sit down with a pharma brand marketer — really sit down — and what you hear is a version of the same frustration, repeated across companies, geographies, and therapeutic areas. The tools do not quite fit. They solve problems that were assumed rather than observed. They were built for a version of the job that exists on a product roadmap, not for the reality of someone managing a dozen priorities, a compliance review, and a campaign deadline at the same time.
This is the central design failure of the industry. Not a lack of ambition. Not a lack of investment. A lack of the right people in the room when the decisions are being made.
Investment Has Outpaced Understanding
Every year, the industry pours more money, more talent, and more conviction into the technology stack. And every year, the gap between what the technology promises and what brand marketers actually experience widens. More tools. More dashboards. More platforms claiming to solve the same problems in slightly different ways. Less of the one thing that would change everything — a real connection to the people the technology is supposed to serve.
That gap does not exist because the industry lacks talent or intent. It exists because the tools being deployed were not built with a deep enough understanding of the environment they are being deployed into. Technology designed at a distance from the problem will always underperform for the person living it.
The User Has Been a Consultant, Not a Co-Creator
The standard model for building pharma tech follows a familiar pattern: research the user, define the requirements, build the product, launch it, gather feedback, iterate. It looks thorough on paper. In practice, it places the most important voice — the brand marketer's — at the edges of the process, while the decisions that shape the product are made in the middle by people who are not living the problem.
The user has been treated as input into the system, not as a builder of it.
By the time a brand manager encounters a finished tool, its assumptions are already set. Feedback at that stage can change how something works. It cannot change what it fundamentally is. And so the cycle continues: a product ships, marketers point out what it misses, the next version corrects for that, and the version after that — but the foundational misunderstanding that started the whole thing is never revisited.
The Knowledge That Cannot Be Briefed
There is a kind of knowledge that only comes from doing the job. Not the strategic knowledge that transfers cleanly into a brief or a presentation — but the operational, ground-level understanding of how things actually behave when the pressure is real and the margin for error is small. The workarounds people have built. The steps that add friction nobody planned for. The features that look essential from the outside but create problems on the inside. The reviews that take longer than they should because of a system designed without that reality in mind.
This knowledge cannot be captured in a survey. It does not surface in a discovery call. It reveals itself only when the people who hold it are genuinely present in the work — early enough, and deeply enough, for what they know to change what gets built.
What Real Collaboration Looks Like
Co-creation is not an advisory board that meets twice a year. It is not a research panel asked to react to something already designed. Real collaboration begins before the first wireframe — when the brand marketer is sitting next to the product manager, the engineer, and the designer, deciding together what the problem is, not just how to solve it.
It looks like marketers helping write the product brief, not just respond to it. Engineers building alongside the people whose workflows their code will shape. Designers learning what a Friday afternoon looks like for a brand manager juggling three campaigns and an MLR review at once. The line between user and builder softens, and what emerges is not a tool handed down from one to the other, but a tool that belongs to both.
This is harder than the standard model. It takes longer at the start. It demands a kind of humility from technology teams that the industry has not always rewarded. But it is the only approach that produces tools people actually want to use — because the people using them helped decide what they would be.
The Marketer's Role in This
This is not only a call to technology builders. It is a call to brand marketers as well. The next generation of pharma marketing technology will not be co-authored unless its users insist on co-authorship — refuse to be consulted at the end, demand a seat at the start, and treat their operational knowledge as the strategic asset it is.
The shift this industry needs will not happen because vendors decide to be more user-centric. It will happen because users decide to be more central.
May 7 Is the Signal
As AI becomes standardised infrastructure across pharma marketing, the gap between tools built for users and tools built with them will widen. Scaling the wrong system only scales the problem. The foundation has to be the user — not as an audience for the product, but as an author of it.
At Doceree, this belief is being translated into action. On May 7, at Health Decode in New York, a new way of building pharma marketing technology — shaped by the people who use it — will be revealed. Not in a boardroom. In a room full of brand marketers who live these problems every day. They will not just witness what emerges. They will have built it.
The people who feel the problems should own the solutions. May 7 is not just a reveal. It is a signal — that how pharma marketing technology gets made is about to change.
— Harshit Jain, MD Founder & Global CEO, Doceree